Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells

Anagrelide is widely used as a therapeutic agent for patients with essential thrombocythemia (ET).[1][1] It was initially developed as an antiplatelet aggregation drug by inhibition of phosphodiesterase III,[2][2] and its primary effect at therapeutic concentrations is on the post-mitotic phase of